Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.
aptamer
early diagnosis
ophthalmology
targeting therapy
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
04
2023
accepted:
19
06
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
epublish
Résumé
Aptamers are widely applied to diagnosis and therapy because of their targeting. However, the current progress of research into aptamers for the treatment of eye disorders has not been well-documented. The current literature on aptamers was reviewed in this study. Aptamer-related drugs and biochemical sensors have been evaluated for several eye disorders within the past decade; S58 targeting TGF-β receptor II and pegaptanib targeting vascular endothelial growth factor (VEGF) are used to prevent fibrosis after glaucoma filtration surgery. Anti-brain-derived neurotrophic factor aptamer has been used to diagnose glaucoma. The first approved aptamer drug (pegaptanib) has been used to inhibit angiogenesis in age-related macular degeneration (AMD) and diabetic retinopathy (DR), and its efficacy and safety have been demonstrated in clinical trials. Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers, such as C promoter binding factor 1, CD44, and advanced end products in AMD and DR, targeting other signal pathway proteins have also been discovered for therapy, and biochemical sensors for early diagnosis have been developed based on aptamers targeting VEGF, connective tissue growth factor, and lipocalin 1. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.
Identifiants
pubmed: 37551274
doi: 10.2147/IJN.S418115
pii: 418115
pmc: PMC10404440
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Aptamers, Nucleotide
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4421-4430Informations de copyright
© 2023 Cao et al.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interest in this research.
Références
Molecules. 2019 Mar 07;24(5):
pubmed: 30866536
Nat Med. 2014 Nov;20(11):1270-8
pubmed: 25282358
Biomaterials. 2018 Mar;157:98-106
pubmed: 29258013
Cochrane Database Syst Rev. 2019 Mar 04;3:CD005139
pubmed: 30834517
J Glaucoma. 2014 Oct-Nov;23(8 Suppl 1):S36-8
pubmed: 25275903
ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9445-9456
pubmed: 33528240
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Anal Bioanal Chem. 2022 Oct;414(24):7291-7297
pubmed: 36029324
PLoS One. 2008 Jul 02;3(7):e2593
pubmed: 18596911
Mol Ther Nucleic Acids. 2016 Aug 30;5(8):e358
pubmed: 27574784
Adv Drug Deliv Rev. 2018 Sep;134:65-78
pubmed: 30125604
Molecules. 2010 Jan 07;15(1):215-25
pubmed: 20110884
Cancer Sci. 2011 May;102(5):991-8
pubmed: 21281402
Mol Cancer Ther. 2006 Jul;5(7):1790-9
pubmed: 16891465
J Cell Physiol. 2006 May;207(2):407-12
pubmed: 16419035
Ophthalmic Res. 2015;54(4):175-80
pubmed: 26492350
Oncogene. 2018 Mar;37(12):1551-1560
pubmed: 29321667
Comput Methods Programs Biomed. 2021 Nov;211:106422
pubmed: 34598080
Ophthalmology. 2016 Jan;123(1):78-85
pubmed: 26499921
Exp Eye Res. 2015 Nov;140:171-178
pubmed: 26368850
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5465-76
pubmed: 26284552
Front Cell Infect Microbiol. 2022 Jun 30;12:818737
pubmed: 35846753
Chem Biol. 1995 Aug;2(8):543-52
pubmed: 9383458
ChemistrySelect. 2017 Mar 1;2(7):2335-2340
pubmed: 29226219
Prog Retin Eye Res. 2007 Sep;26(5):470-85
pubmed: 17690002
Mol Ther Nucleic Acids. 2019 Sep 6;17:819-828
pubmed: 31454678
Ophthalmology. 2010 Mar;117(3):500-11
pubmed: 20022638
Pharmaceutics. 2022 Dec 13;14(12):
pubmed: 36559275
Biosens Bioelectron. 2022 Nov 1;215:114566
pubmed: 35863136
Exp Eye Res. 2020 Apr;193:107977
pubmed: 32081668
Transl Vis Sci Technol. 2019 Jan 25;8(1):14
pubmed: 30697465
JAMA Ophthalmol. 2019 May 1;137(5):483-490
pubmed: 30703203
Exp Eye Res. 2015 Apr;133:37-48
pubmed: 25819453
Nature. 1992 Feb 6;355(6360):564-6
pubmed: 1741036
J Mol Evol. 2015 Dec;81(5-6):150-61
pubmed: 26530075
Lancet. 2018 Sep 29;392(10153):1147-1159
pubmed: 30303083
Cancers (Basel). 2022 Aug 25;14(17):
pubmed: 36077643
Pharm Res. 2004 Dec;21(12):2234-46
pubmed: 15648255
Biosens Bioelectron. 2018 Jul 1;110:23-37
pubmed: 29579646
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2328-33
pubmed: 16452172
Front Cell Dev Biol. 2022 Nov 01;10:1048148
pubmed: 36393853
Science. 1990 Aug 3;249(4968):505-10
pubmed: 2200121
Molecules. 2021 Oct 28;26(21):
pubmed: 34770931
Nucleic Acid Ther. 2020 Dec;30(6):365-378
pubmed: 32881630
Angiogenesis. 2018 Nov;21(4):883-900
pubmed: 30014172
Invest New Drugs. 2014 Feb;32(1):178-87
pubmed: 24242861
J Manag Care Spec Pharm. 2015 Sep;21(9):735-41
pubmed: 26308221
Biosens Bioelectron. 2018 Apr 15;102:57-62
pubmed: 29125972
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:61-79
pubmed: 28061688
Front Mol Biosci. 2022 Aug 23;9:985434
pubmed: 36081847
BMC Ophthalmol. 2018 May 30;18(1):130
pubmed: 29843663
Chem Immunol Allergy. 2007;92:4-10
pubmed: 17264478
ACS Appl Mater Interfaces. 2022 Jan 12;14(1):32-40
pubmed: 34928139
Surv Ophthalmol. 2008 May-Jun;53(3):187-202
pubmed: 18501266
Biochem Biophys Rep. 2019 May 01;18:100642
pubmed: 31080896
Invest Ophthalmol Vis Sci. 2012 Oct 05;53(11):6897-903
pubmed: 22899759
Nanomedicine. 2020 Oct;29:102260
pubmed: 32629041
Biosens Bioelectron. 2019 Oct 1;142:111475
pubmed: 31288216
J Am Optom Assoc. 1995 Jul;66(7):435-41
pubmed: 7560732
Pharmaceutics. 2021 Oct 13;13(10):
pubmed: 34683964
J Chem Phys. 2022 Jun 28;156(24):244103
pubmed: 35778075
Front Bioeng Biotechnol. 2022 May 09;10:850412
pubmed: 35615476
JAMA. 2014 May 14;311(18):1901-11
pubmed: 24825645
Anal Chem. 2021 May 18;93(19):7369-7377
pubmed: 33960774
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):290-9
pubmed: 12506087
Bol Med Hosp Infant Mex. 2016 Nov - Dec;73(6):372-379
pubmed: 29421281
Nucleic Acids Res. 2022 Apr 8;50(6):3083-3095
pubmed: 35293579
Front Immunol. 2022 Aug 08;13:918522
pubmed: 36003405
Pharm Res. 2000 Dec;17(12):1503-10
pubmed: 11303960
Pharmacol Rev. 2004 Dec;56(4):549-80
pubmed: 15602010
Exp Eye Res. 2011 Nov;93(5):689-99
pubmed: 21907194
Nippon Ganka Gakkai Zasshi. 2014 Sep;118(9):773-82
pubmed: 25318186
Int J Ophthalmol. 2022 May 18;15(5):690-700
pubmed: 35601180
Cells. 2021 Jun 28;10(7):
pubmed: 34203430
Int J Pharm. 2013 Nov 18;456(2):499-507
pubmed: 23999222
Anal Biochem. 2011 Aug 15;415(2):175-81
pubmed: 21530479
Clin Dermatol. 2015 Mar-Apr;33(2):140-6
pubmed: 25704934
Ophthalmology. 2021 Apr;128(4):576-586
pubmed: 32882310
RSC Adv. 2018 Sep 7;8(55):31510-31514
pubmed: 35548247
Eur J Ophthalmol. 2011;21 Suppl 6:S3-9
pubmed: 23264323
Am J Ophthalmol. 2022 Nov;243:98-108
pubmed: 35932820
Zhonghua Yan Ke Za Zhi. 2015 Apr;51(4):314-8
pubmed: 26081237
Front Pharmacol. 2022 May 20;13:875662
pubmed: 35668928
Aging (Albany NY). 2020 May 23;12(10):8837-8857
pubmed: 32452828
Eur J Clin Invest. 2003 Oct;33(10):833-9
pubmed: 14511353
Microvasc Res. 2013 Nov;90:64-70
pubmed: 24012635
Mol Ther. 2016 Nov;24(11):1974-1986
pubmed: 27506449
ACS Appl Mater Interfaces. 2021 Mar 3;13(8):9306-9315
pubmed: 33030015
Ophthalmic Res. 1998;30(6):333-9
pubmed: 9731114
Biosens Bioelectron. 2020 Dec 1;169:112607
pubmed: 32947081
N Engl J Med. 2004 Dec 30;351(27):2805-16
pubmed: 15625332
Mol Vis. 2012;18:2783-95
pubmed: 23213278
Saudi J Ophthalmol. 2015 Oct-Dec;29(4):287-91
pubmed: 26586980
Cochrane Database Syst Rev. 2018 Oct 16;10:CD007419
pubmed: 30325017
Curr Med Chem. 2023;30(30):3441-3471
pubmed: 36043748
J Insect Sci. 2012;12:129
pubmed: 23448195
Ophthalmology. 2017 Feb;124(2):224-234
pubmed: 28029445
Transl Vis Sci Technol. 2020 Sep 11;9(10):12
pubmed: 32974084
Lancet. 2010 Jul 10;376(9735):124-36
pubmed: 20580421
PLoS One. 2015 Jul 15;10(7):e0132407
pubmed: 26176230
Biosensors (Basel). 2019 Oct 14;9(4):
pubmed: 31615077
Ocul Oncol Pathol. 2016 Oct;2(4):262-269
pubmed: 27843907
Surv Ophthalmol. 2020 Mar - Apr;65(2):119-132
pubmed: 31634487